We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mycoplasmas Frequently Cause Congenital Fetal Infection

By Labmedica staff writers
Posted on 15 Jan 2008
Premature babies should be screened for genital mycoplasma, which are a frequent cause of congenital infection. More...


Mycoplasmas are surface parasites of the human respiratory and urogenital tracts. They are spherical to filamentous cells with no cell walls. Twenty-three percent of neonates born between 23 and 32 weeks of gestation were found to have positive umbilical blood cultures for two genital mycoplasmas--Ureaplasma urealyticum and Mycoplasma hominis.

Although these two mycoplasmas are found in 80% of vaginal and cervical fluids, infants are not generally screened for these infections. The finding that about one-quarter of early preterm infants is already infected at birth is important for reducing adverse outcomes. These newborns had a higher incidence of neonatal systemic inflammatory response syndrome (SIRS), higher incidence of bronchopulmonary dysplasia (BPD), higher serum concentrations of interleukin (IL)-6, and more evidence of placental inflammation than those with negative cultures. It was found that the earlier the gestational age at delivery, the higher the rate of a positive umbilical cord blood culture.

The study was performed by the Alabama Preterm Birth Study (USA), and included 457 consecutive deliveries of infants born at 23-32 weeks' gestation from 1996 to 2001. It focused on a subset of 351 women/infant pairs in the population who had umbilical cord blood cultures for U. urealyticum and M. hominis.

Robert Goldenberg, M.D., professor, department of obstetrics and gynecology, Drexel University College of Medicine (Philadelphia, PA, USA) stated, "Given the frequency of these infections and their association with SIRS and [probably] with BPD, it seems reasonable to determine if infants in these categories would benefit from routine culture for U. urealyticum and/or M. hominis and subsequent treatment with an antibiotic effective against these organisms. Similarly, we question whether treatment of women likely to deliver an early gestational age infant with an antibiotic effective against these organisms might reduce subsequent neonatal morbidity and mortality.”

The study appeared in the January 2008 issue of the American Journal of Obstetrics & Gynecology. In an accompanying editorial, professors Roberto Romero, M.D., form the Center of Molecular Medicine, Wayne State University (Detroit, MI, USA) and Thomas J. Garite, from the University of California (Irvine, CA, USA) wrote, "The initial uncertainties of whether genital mycoplasmas can cause fetal/neonatal disease are disappearing in light of the accumulating evidence that these microorganisms have been implicated in neonatal sepsis, pneumonia, meningitis, and brain damage. Moreover, colonization of the neonatal respiratory tract with these organisms is a risk factor for chronic lung disease. The detection of genital mycoplasmas is not part of routine clinical practice in obstetrics and neonatology. Similarly, standard treatment for suspected neonatal sepsis does not include antibiotics effective against these microorganisms.”

Editor's note: certain species of U. urealyticum have now been classified as U. parvum, a new species.


Related Links:
Drexel University College of Medicine
Wayne State University
University of California, Irvine

New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Human Estradiol Assay
Human Estradiol CLIA Kit
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.